Amarantus BioScience announced that Adam J. Simon, Ph.D., has been appointed to its Board of Advisors. Dr. Simon is a world-renowned expert in working with Alzheimer’s disease biomarkers, and also has significant expertise in the development of in-vitro diagnostics; these qualifications make him a welcome addition to the biotechnology, which focuses on discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis.
Gerald E. Commissiong, Amarantus’s President and CEO, remarked, “Dr. Simon will play an important role in the development of our LymPro diagnostic blood test for Alzheimer’s disease. He is a recognized leader in the discovery of Alzheimer’s biomarkers, and has advised both major pharmaceutical companies and early stage research companies on their clinical programs and regulatory submissions. Dr. Simon is also an entrepreneur in his own right, and understands the specific challenges and opportunities we face here at Amarantus.”
Dr. Simon founded and is currently the president of AJ Simon Enterprises, LLC, a consulting firm serving pharmaceutical and biotechnology clients. He also founded and is the CEO of Cerora, Inc., a healthcare information technology company that develops medical devices and services to assess brain health, including Traumatic Brain Injury. Mr. Simon spent over 13 years at Merck Research Laboratories, where he served as a Senior Research Fellow in Integrative Systems Neuroscience and Biomarkers and in Alzheimer’s disease research. He has also been a visiting scientist at Princeton University.
Dr. Simon earned Bachelor’s degrees in Physics and Mathematics from the University of Rochester, and has a Doctorate in Physics from the University of Chicago. He holds four patents related to medical research and has published more than 60 articles in scientific and medical journals.
For more information, visit www.amarantus.com
Let us hear your thoughts below: